|
Actelion will not develop Tracleer for melanoma
|
|
|
Posted on
Dec 17 2007 6:13 AM
by
Asif
|
Swiss drug maker Actelion said on Monday it would not develop its bosentan medicine, sold as Tracleer, as a treatment for metastatic melanoma, a form of skin cancer.
Actelion said in a statement on Monday that preliminary efficacy data generated in the proof-of-concept study evaluating bosentan in metastatic melanoma did not support a full clinical development program.
|
|
No comment found for this blog
|
|